Clinical trial
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
NCT00287495 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00287495 |
|---|---|
| Title | BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma |
| Official title | Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kaposi's Sarcoma, HHV-8, KSHV |
| Intervention type | Drug |
| Interventions | BAY 43-9006 |
| Enrollment | 10 |
| Start date | Feb 2, 2006 |
| Primary completion | Sep 21, 2012 |
| Completion | Oct 18, 2017 |
| First posted | Feb 6, 2006 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: